We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is ADC Therapeutics SA (ADCT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
ADC Therapeutics SA is one of 932 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 36.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ADCT has moved about 8.2% on a year-to-date basis. At the same time, Medical stocks have gained an average of 7.5%. This means that ADC Therapeutics SA is performing better than its sector in terms of year-to-date returns.
Agenus (AGEN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 35.4%.
Over the past three months, Agenus' consensus EPS estimate for the current year has increased 77.2%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ADC Therapeutics SA belongs to the Medical - Biomedical and Genetics industry, which includes 453 individual stocks and currently sits at #99 in the Zacks Industry Rank. This group has gained an average of 18.9% so far this year, so ADCT is slightly underperforming its industry in this area. Agenus is also part of the same industry.
ADC Therapeutics SA and Agenus could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is ADC Therapeutics SA (ADCT - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
ADC Therapeutics SA is one of 932 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 36.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ADCT has moved about 8.2% on a year-to-date basis. At the same time, Medical stocks have gained an average of 7.5%. This means that ADC Therapeutics SA is performing better than its sector in terms of year-to-date returns.
Agenus (AGEN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 35.4%.
Over the past three months, Agenus' consensus EPS estimate for the current year has increased 77.2%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, ADC Therapeutics SA belongs to the Medical - Biomedical and Genetics industry, which includes 453 individual stocks and currently sits at #99 in the Zacks Industry Rank. This group has gained an average of 18.9% so far this year, so ADCT is slightly underperforming its industry in this area. Agenus is also part of the same industry.
ADC Therapeutics SA and Agenus could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.